SCHEMBL16244286

SCHEMBL16244286

Cc1cc(Br)cn2c(C)nnc12

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
RXFP1 Q9HBX9 1/20 0.40
TRPA1 O75762 1/20 0.37
PRNP P04156 4/20 0.35
PABPC1 P11940 2/20 0.35
HTR6 P50406 1/20 0.34
BRD4 O60885 7/20 0.34
BRD2 P25440 7/20 0.34
BRD3 Q15059 7/20 0.34
CREBBP Q92793 7/20 0.34
RAD52 P43351 1/20 0.34
GALR3 O60755 1/20 0.32
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16268761 0.86 MEN1 (0.36) L3MBTL1RXFP1TRPA1BRD4MAPT
SCHEMBL20160086 0.81 ATAD2 (0.36) L3MBTL1BRD4BRD2BRD3CREBBP
SCHEMBL20160237 0.81 L3MBTL1 (0.33) L3MBTL1BRD4BRD2BRD3
SCHEMBL16259902 0.79 BRD4 (0.35) BRD4BRD2BRD3CREBBPNPC1
SCHEMBL31155678 0.78 L3MBTL1 (0.41) L3MBTL1RXFP1TRPA1PRNPPABPC1
SCHEMBL16268588 0.78 LMNA (0.39) L3MBTL1RXFP1PRNPBRD4BRD2
SCHEMBL16268766 0.77 L3MBTL1 (0.40) L3MBTL1RXFP1TRPA1PRNPPABPC1
SCHEMBL16244913 0.76 BRD3 (0.34) BRD4BRD2BRD3CREBBPNPC1
SCHEMBL16267911 0.73 RXFP1 (0.36) RXFP1BRD4BRD2BRD3CREBBP
SCHEMBL21227653 0.72 CYP1A2 (0.41) BRD4BRD2BRD3CREBBPNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709722-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 EP disclosed
WO-2024233547-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2024-11-14 WO disclosed
CN-110997670-B [1,2,4] triazolo [4,3-a ] pyridyl substituted indole compounds 百时美施贵宝公司 2022-11-01 CN disclosed
EP-3661934-B1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2022-06-01 EP disclosed
EP-3661934-B1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2022-06-01 EP disclosed
US-11130756-B2 [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2021-09-28 US disclosed
US-11130756-B2 [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2021-09-28 US disclosed
US-20200369661-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-11-26 US disclosed
US-20200369661-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-11-26 US disclosed
EP-3661934-A1 [1,2,4]TRIAZOLO[4,3-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS Bristol-Myers Squibb Company (US) 2020-06-10 EP disclosed
US-20160095843-A1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2016-04-07 US disclosed
US-20160095843-A1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2016-04-07 US disclosed
US-8975417-B2 Pyrazolopyrrolidine derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2015-03-10 US disclosed
US-8975417-B2 Pyrazolopyrrolidine derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2015-03-10 US disclosed
US-8975417-B2 Pyrazolopyrrolidine derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2015-03-10 US disclosed
WO-2014191906-A1 PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2014-12-04 WO disclosed
WO-2014191896-A1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2014-12-04 WO disclosed
US-20140349990-A1 Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2014-11-27 US disclosed
US-20140349990-A1 Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2014-11-27 US disclosed
US-20140349990-A1 Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2014-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160095843-A1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE PKD1, PKD2, REN L3MBTL1 4859/4885RXFP1 3158/4885TRPA1 651/4885
US-11130756-B2 [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds TLR7, TLR1, TLR4 L3MBTL1 4488/4885RXFP1 126/4885TRPA1 78/4885
US-20140349990-A1 Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease PKD1, PKD2, REN L3MBTL1 4860/4885RXFP1 3117/4885TRPA1 665/4885
US-20200369661-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS TLR7, TLR1, TLR4 L3MBTL1 4488/4885RXFP1 126/4885TRPA1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.